Vonoprazan-d3 (fumarate)
Vonoprazan-d3 fumarate is the deuterium labeled Vonoprazan fumarate. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+, K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease[1][2].
Product Specifications
UNSPSC
12352005
Target
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Field of Research
Others
Solubility
10 mM in DMSO
Smiles
OC(/C=C/C(O)=O)=O.O=S(N1C(C2=C(C=CC=C2)F)=CC(CNC([2H])([2H])[2H])=C1)(C3=CN=CC=C3)=O
Molecular Formula
C21H17D3FN3O6S
Molecular Weight
464.48
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45 / LCA (2B11 + PD7/26), CF568 conjugate, 0.1mg/mL
